855303-RNA Biomarker Validation

NCT ID: NCT06872775

Last Updated: 2026-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-25

Study Completion Date

2028-08-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the accuracy of using RNA in blood as a way to forecast new fracture healing outcome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will follow a registry + biospecimen collection format. Subjects will be enrolled at participating Sites as they present for care for new traumatic appendicular skeletal fractures (0 - ≤7 Days post-injury) and will provide blood specimens for study analysis and future use at up to 4 post-injury windows of treatment (i.e., Window 1, 0 - ≤7 Days; Window 2, 8 - ≤14 days; Window 3, 15 - ≤42 Days; and Window 4, 43 - ≤84 Days post-injury).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fractures, Bone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

New Traumatic Fractures

Anyone age 18 or over presenting to participating sites for care of new, traumatic appendicular fractures.

Blood draws to assess RNA expression levels

Intervention Type OTHER

None. Standard of Care (SOC) only.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood draws to assess RNA expression levels

None. Standard of Care (SOC) only.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible to participate in this study, a potential subject must meet ALL of the following criteria:

1. Provision of informed consent for study participation for self in the English language as indicated by a signed and dated, current, and IRB-approved Informed Consent Form (ICF) from

1. patients making their own SOC clinical decisions prior to the time of the 1st blood sample collection, or
2. persons initially unable to make their own SOC clinical decisions, who regain capacity to make clinical care decisions after study blood sample collection during the enrollment window and/or before hospital discharge.
2. Patient is expected to receive follow-up SOC fracture care at the Site.
3. Either biological sex at birth (i.e., male or female).
4. Any self-determined gender or sexual preference.
5. Any race and/or ethnicity combination.
6. Age 18 years or older at the time of enrollment; no maximum age.
7. Body weight estimated to be or measured at ≥110 lbs.
8. Presentation for care within 7 calendar days of injury for at least one new traumatic fracture of any bone in the appendicular skeleton with or without additional fractures of the appendicular or axial skeleton and with or without any other traumatic injuries.

1. A qualifying fracture:

* May be open or closed as locally defined per SOC.
* May be displaced or non-displaced per SOC.
* Must result from blunt or penetrating trauma.
* May not be in a location of the body that was chronically paralyzed pre-trauma or has become permanently paralyzed because of the trauma.
* Does not include traumatic amputation above the fracture Site for qualifying fractures
2. Index treatment plan:

* May be operative or non-operative.
* May include staged treatment with or without the use of external fixators, and/or antibiotic beads, and/or other planned intervention.
* Does not include hemi- or total arthroplasty to treat the qualifying fracture.
* Does not include amputation above the qualifying fracture.
9. In good general health as evidenced by clinical presentation and/or medical history and without any diagnoses that preclude a life expectancy of at least 2 years after injury.
10. No healed or unhealed fractures within 12 months prior to the event resulting in the qualifying fracture.
11. Blood collection through venipuncture at the volume and frequency per protocol is not contraindicated either through past medical history or current clinical status
12. 45 CFR 46 Subpart B: For females of reproductive potential: not pregnant at the time of study enrollment.
13. CFR 46 Subpart C: Does not meet the CFR definition of Prisoner.
14. Other vulnerable populations:

1. Not an individual with pre-existing or newly acquired permanently impaired decision-making capacity , and/or
2. Not an individual who would be considered an economically or educationally disadvantaged person prior to the qualifying injury as determined by the Site study team per Site standards.

\-

Exclusion Criteria

An individual who meets ANY of the following criteria will be excluded from participation in this study:

1. Enrolled in another research study that requires any study-specific blood draws from 0 - ≤84 Days post-injury or a study that prohibits co-enrollment of any kind.
2. Traumatic injuries at presentation are limited to soft tissue injuries and/or axial skeletal fractures.
3. The presentation appendicular fractures is a result of pathological not traumatic mechanism
4. Any other circumstances that in the opinion of the PI would either put the successful completion of the study at risk, and/or which makes study participation unduly burdensome to the Subject.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PharPoint Research, Inc.

INDUSTRY

Sponsor Role collaborator

Children's Hospital of Philadelphia

OTHER

Sponsor Role collaborator

Cooperative Human Tissue Network - Eastern Division (CHTN-ED)

UNKNOWN

Sponsor Role collaborator

Osetomics, LLC

UNKNOWN

Sponsor Role collaborator

Resonant Clinical/Therapak, Claremont, California

UNKNOWN

Sponsor Role collaborator

ResearchDx, Irvine, CA

UNKNOWN

Sponsor Role collaborator

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Samir Mehta, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Annamarie D Horan, MPA, PhD

Role: STUDY_DIRECTOR

University of Pennsylvania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California, Davis Medical Center

Sacramento, California, United States

Site Status

Indiana University

Bloomington, Indiana, United States

Site Status

University of Missouri

Columbia, Missouri, United States

Site Status

Wake Forest University Health Sciences/Advocate Health

Charlotte, North Carolina, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

855303

Identifier Type: -

Identifier Source: org_study_id

UPCC-02924

Identifier Type: OTHER

Identifier Source: secondary_id

50526

Identifier Type: OTHER

Identifier Source: secondary_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fall, Fracture and Frailty
NCT05712252 ACTIVE_NOT_RECRUITING